

Figure W1. Adiponectin and leptin treatments do not modulate growth of MCF10A cells in a significant manner. MCF10A cells were treated with 100 ng/ml leptin (L) and 10 μ g/ml adiponectin (Adn) alone and in combination (L + Adn) and subjected to clonogenicity assay. Colonies containing >50 normal-appearing cells were counted. Adiponectin did not modulate growth of MCF10A in a significant manner.




Figure W2. Adenovirus-adiponectin (Ad-Adn) treatment increases expression of LKB1 in breast cancer cells. MDA-MB-231 cells were treated with Ad-luc (luciferase control) or Ad-Adn (10^8 pfu) for various time intervals as indicated. Total protein was isolated and equal amounts of proteins were resolved by SDS-PAGE and subjected to immunoblot analysis using specific antibodies for LKB1. The blots are representative of multiple independent experiments. Ad-Adn treatment increases LKB1 expression in MDA-MB-231 breast cancer cells.




Figure W3. Rosiglitazone inhibits clonogenicity and soft-agar growth of breast cancer cells. (A) Breast cancer cells (MDA-MB-468 and T47D) were treated with various concentrations of rosiglitazone as indicated and subjected to clonogenicity assay. Untreated control cells are denoted as control. Colonies containing >50 normal-appearing cells were counted. Rosiglitazone inhibited clonogenic potential of breast cancer cells. (B) Breast cancer cells (MCF7, MDA-MB-231, and T47D) were treated with various concentrations of rosiglitazone as indicated and subjected to soft-agar 3D colony formation assay. Results are expressed as average number of colonies counted (in six microfields). * $P < .005$, compared with untreated controls. Rosiglitazone inhibited anchorage-independent growth of breast cancer cells.




Figure W4. Rosiglitazone do not modulate growth of MCF10A and MCF12A cells in a significant manner. MCF10A and MCF12A cells were treated with various concentrations of rosiglitazone as indicated and subjected to clonogenicity assay. Untreated control cells are denoted as control. Colonies containing >50 normal-appearing cells were counted. Rosiglitazone did not modulate growth of MCF10A and MCF12A cells significantly.




Figure W5. Rosiglitazone increases phosphorylation of AMPK in breast cancer cells. Breast cancer cells (MDA-MB-468) were treated with 50 μ M rosiglitazone for various intervals of time as indicated. Untreated cells are denoted as 0. Total protein was isolated and equal amounts of proteins were resolved by SDS-PAGE and subjected to immunoblot analysis using specific antibodies for pAMPK. The blots are representative of multiple independent experiments. Rosiglitazone treatment increases phosphorylation of AMPK in MDA-MB-468 breast cancer cells.